T2 Biosystems
TTOO

$2.19

0.45%

Market Cap: $38.3M

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,728 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

2,315% more capital invested

Capital invested by funds: $520K [Q1] → $12.6M (+$12M) [Q2]

167% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 3

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

11% more funds holding

Funds holding: 19 [Q1] → 21 (+2) [Q2]

10.26% more ownership

Funds ownership: 3.51% [Q1] → 13.77% (+10.26%) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$5

128%

upside

Avg. target

$5

128%

upside

High target

$5

128%

upside

1 analyst rating

0 positive

0%

1 neutral

100%

0 negative

0%

Canaccord Genuity

Kyle Mikson

57% 1-year accuracy

12 / 21 met price target

128%upside

$5

Hold

Maintained

30 Jul 2024

See Analyst Rankings

Financial journalist opinion

T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union

LEXINGTON, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has successfully defended against an opposition filed against a key patent for its direct-from-whole blood detection method in the European Union.

T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union

T2 Biosystems to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

LEXINGTON, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming H.C. Wainwright 26th Annual Global Investment Conference.

T2 Biosystems to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

T2 Biosystems to Attend Upcoming Investor Conferences

LEXINGTON, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in two upcoming investor conferences in August 2024:

T2 Biosystems to Attend Upcoming Investor Conferences

T2 Biosystems, Inc. (TTOO) Q2 2024 Earnings Call Transcript

T2 Biosystems, Inc. (NASDAQ:TTOO ) Q2 2024 Earnings Conference Call July 29, 2024 4:30 PM ET Company Participants Trip Taylor - Investor Relations John Sperzel - Chairman & Chief Executive Officer John Sprague - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Operator Greetings, and welcome to T2 Biosystems, Inc. Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

T2 Biosystems, Inc. (TTOO) Q2 2024 Earnings Call Transcript

T2 Biosystems Announces Commercial Expansion Through Malaysia and Indonesia Distributor

LEXINGTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of a territory exclusive distribution agreement in Malaysia and Indonesia. Under the terms of the agreement, T2 Biosystems will sell the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, and the T2Resistance® Panel through the newly appointed distributor.

T2 Biosystems Announces Commercial Expansion Through Malaysia and Indonesia Distributor

T2 Biosystems to Report Second Quarter 2024 Financial Results and Business Updates on July 29, 2024

LEXINGTON, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the second quarter 2024 and business updates after market close on Monday, July 29, 2024.

T2 Biosystems to Report Second Quarter 2024 Financial Results and Business Updates on July 29, 2024

T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements

LEXINGTON, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) on May 21, 2024 informing the Company that it has regained compliance with the market value of listed securities (“MVLS”) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the “Rule”) for continued listing on the Nasdaq Capital Market.

T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements

T2 Biosystems Announces Closing of $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

LEXINGTON, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 2,025,317 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 2,025,317 shares of common stock and short-term series B warrants to purchase up to 2,025,317 shares of common stock at a purchase price of $3.95 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants have an exercise price of $3.70 per share and are exercisable immediately upon issuance. The series A warrants will expire five and one-half years from the date of issuance and the short-term series B warrants will expire eighteen months from the date of issuance.

T2 Biosystems Announces Closing of $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

T2 Biosystems Announces $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

LEXINGTON, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 2,025,317 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 2,025,317 shares of common stock and short-term series B warrants to purchase up to 2,025,317 shares of common stock at a purchase price of $3.95 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants will have an exercise price of $3.70 per share and will be exercisable immediately upon issuance. The series A warrants will expire five and one-half years from the date of issuance and the short-term series B warrants will expire eighteen months from the date of issuance. The private placement is expected to close on or about May 17, 2024, subject to the satisfaction of customary closing conditions.

T2 Biosystems Announces $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

T2 Biosystems Announces CRG's Conversion from Preferred Stock to Common Stock

LEXINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that entities affiliated with CRG Servicing LLC (“CRG”) have converted Series A and Series B Convertible Preferred Stock to Common Stock.

T2 Biosystems Announces CRG's Conversion from Preferred Stock to Common Stock

See News Rankings